Santillo, Alexander F.
Leuzy, Antoine
Honer, Michael
Landqvist Waldö, Maria
Tideman, Pontus
Harper, Luke
Ohlsson, Tomas
Moes, Svenja
Giannini, Lucia
Jögi, Jonas
Groot, Colin
Ossenkoppele, Rik
Strandberg, Olof
van Swieten, John
Smith, Ruben
Hansson, Oskar
Funding for this research was provided by:
Swedish Research Council (2016-00906)
Knut och Alice Wallenbergs Stiftelse (2017-0383)
Marcus och Amalia Wallenbergs minnesfond (2015.0125)
Strategic Research Area MultiPark
Swedish Alzheimer Foundation (AF-939932)
Swedish Brain Foundation (FO2021-0293)
The Parkinson foundation of Sweden (1280/20)
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
Skåne University Hospital Foundation (2020-O000028)
Lund University
Article History
Received: 25 March 2022
Accepted: 28 November 2022
First Online: 14 December 2022
Declarations
:
: OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Fujirebio, Genentech, Novartis, Roche, and Siemens. MH and SM are employees of F. Hoffmann-La Roche.